Every material Form 8-K Organogenesis Holdings Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Organogenesis reported third quarter 2026 net product revenue of $45.5 million, down 70% from $150.5 million a year earlier, and a net loss of $29.6 million, compared with net income of $21.6 million in the prior-year quarter. The company also updated its full-year 2026 revenue outlook to $179.4 million to $200.0 million, a decline of 65% to 68%, which it said reflects a more measured fourth-quarter recovery than its prior guidance assumed.
Net product revenue was $45.5 million for the quarter ended September 30, 2026, versus $150.5 million a year earlier; Advanced Wound Care fell 73% to $38.2 million.
Net loss was $29.6 million, or $(0.25) per share, versus net income of $21.6 million, or $0.11 per share, in the third quarter of 2025.
As of September 30, 2026, cash, cash equivalents and restricted cash totaled $26.9 million, with no outstanding debt obligations.
Full-year 2026 net revenue guidance is $179.4 million to $200.0 million, versus $564.2 million in 2025.
Organogenesis entered an at-the-market sales agreement with BTIG and Citizens JMP that lets it sell Class A common stock worth up to $75 million through the agents over time. The company is not obligated to sell any shares, so any sales would depend on its instructions and would add to the number of shares outstanding.
Agreement dated August 6, 2026, with BTIG, LLC and Citizens JMP Securities, LLC as sales agents
Aggregate offering price of up to $75,000,000 under a prospectus supplement dated August 6, 2026
Agents receive a commission of up to 3.0% of gross sales price per share sold
Shares are offered under a Form S-3 shelf registration effective August 15, 2024; the company has no obligation to sell
Organogenesis reported second-quarter 2026 net product revenue of $42.8 million, down 58% from $100.8 million a year earlier, and a net loss of $96.3 million, or $(0.77) per share, compared with a net loss of $9.4 million, or $(0.10) per share, in the second quarter of 2025. The company also lowered its full-year 2026 total net revenue outlook to $179.0 million to $215.0 million, a decline of 62% to 68% from 2025, with management saying the pace of recovery is slower than it expected.
Net product revenue of $42.8 million, down 58% from $100.8 million; Advanced Wound Care fell 61% to $36.1 million
Net loss of $96.3 million, or $(0.77) per share, including income tax expense of $45.4 million
FY2026 total net revenue guidance of $179.0 million to $215.0 million, a 62% to 68% decline from $564.2 million in 2025; prior guidance assumed a 45% to 52% decline
Cash, cash equivalents and restricted cash of $46.8 million at June 30, 2026, with no outstanding debt obligations
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Organogenesis Holdings Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →